Numerous studies did indeed show that AD patients display characteristic CSF changes with decreased levels of β-amyloid1-42 (Aβ42) and elevated levels of total tau protein (tau) and its phosphorylated form at threonine 181 (p-tau)[7,9,10]. This evidence concerns the gene MAPT and Alzheimer disease.